{"record_key":"thendor-therapeutics","identifier":"thendor-therapeutics","external_key":null,"title":"Thendor Therapeutics","summary":null,"url":"https://inventions.pitt.edu/startups/thendor-therapeutics","json_url":"https://inventions.pitt.edu/startups/thendor-therapeutics.json","object_key":"startups","description":"Thendor Therapeutics is an early-stage company developing peptide-based medicines intended to halt or reverse fibrosis and restore healthy tissue function across a range of fibrotic diseases. [1]: https://mtec-sc.org/members/thendor-therapeutics-inc\nIts areas of focus include pulmonary fibrosis, urological fibrosis through its subsidiary Thenduro, systemic fibrotic diseases driven by shared biological pathways, and exposure-induced fibrosis. The company was co-founded by fibrosis researcher Carol Feghali-Bostwick, who serves as acting chief scientific officer, together with CEO Steven King and CFO Paul Lytle. [2]: https://www.thendortx.com/leadership-team-1","attributes":[{"key":"website","label":"Website","values":["https://www.thendortx.com"]},{"key":"sector","label":"Sector","values":["Therapeutics"]},{"key":"therapeutic_areas","label":"Therapeutic Areas","values":["Respiratory"]},{"key":"therapeutic_indications","label":"Therapeutic Indications","values":["Pulmonary fibrosis","Urological fibrosis","Systemic fibrotic disease"]},{"key":"founders","label":"Founders","values":["Carol Feghali-Bostwick","Steven King","Paul Lytle"]}],"related":[]}